Prognia
Drug Database
🇪🇺EU · EMAOpinionATC: L01XL10

Adstiladrin(nadofaragene firadenovec)

Non-Muscle Invasive Bladder Neoplasms

Marketing Authorisation Holder: Ferring Pharmaceuticals A/S

INN: nadofaragene firadenovec

Indication

Treatment of adult patients with high-grade (HG), Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Adstiladrin — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.